The original call
Original year: 2006
2026 assessment
Scorecard verdict: Largely right
Largely right, and the direction was dead on. Personalized medicine and pharmacogenetics are now central to oncology, rare disease, and a growing list of conditions. Targeted therapies based on genetic markers are routine. The thesis was correct. The only reason this isn’t a flat-out “nailed it” is timing : “this more than anything will dominate” the agenda was true for the science, slower for the system. But as a north star for where the whole industry was heading, this one holds up beautifully twenty years on.